Related Experiment Videos
Phase II evaluation of aclacinomycin-A in advanced ovarian carcinoma
S Martino1, D A Decker, H E Hynes
1Wayne State University, School of Medicine, Division of Medical Oncology, Detroit, Michigan.
Investigational New Drugs
|December 1, 1987
Abstract:
Sixteen women with advanced epithelial ovarian carcinoma were treated with Aclacinomycin-A 40 mg/M2 given as a weekly infusion for four consecutive weeks followed by a two week rest period. All had failed prior chemotherapy. No responses were observed. Nausea and vomiting were the most frequent side effect. Myelosuppression was minimal. This dose and schedule of Aclacinomycin-A are not recommended for further trials in ovarian carcinoma.